Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Corhythm Inc.
Brief profiles of these recently formed companies: BioCritica, Entericon, Radisens Diagnostics and Sova Pharmaceuticals.
Protectimmun GMBH aims to leverage findings of a large epidemiological study showing that people exposed early in life to farms have reduced tendency to develop respiratory and other allergies. The German start-up thinks a component of barn dust can help train the human immune system so that it never perceives ordinary environmental substances as allergens.
This article was adapted from "Top Device Stories of 2010: Waiting for the Other Shoes to Fall," in the January 2011 issue of IN VIVO.
Overall in 2010, caution was the watchword for private investors, placing fewer dollars in fewer medtech deals compared to 2009. A total of $1.86 billion in private money was raised by medical device companies in 2010, a big drop from the $2.86 billion placed in the industry in 2009. Deal volume was down commensurately; there were 139 private medical device financings, compared to 207 in 2009. Investment dollars were apportioned, for the most part, in the usual fashion, with the largest proportion going into cardiovascular deals, followed by orthopedics. There were some surprises however, as a few categories, once avoided like the plaque, showed new investor interest.
- Site Specific
- Drug Delivery
- Diagnostic Equipment & Supplies
- Implantable Devices